AR034772A1 - Preparacion de los compuestos de aminopirimidina - Google Patents

Preparacion de los compuestos de aminopirimidina

Info

Publication number
AR034772A1
AR034772A1 ARP020102617A ARP020102617A AR034772A1 AR 034772 A1 AR034772 A1 AR 034772A1 AR P020102617 A ARP020102617 A AR P020102617A AR P020102617 A ARP020102617 A AR P020102617A AR 034772 A1 AR034772 A1 AR 034772A1
Authority
AR
Argentina
Prior art keywords
reacting
reaction product
aminopirimidine
compounds
preparation
Prior art date
Application number
ARP020102617A
Other languages
English (en)
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of AR034772A1 publication Critical patent/AR034772A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Abstract

Un compuesto de 2-(N-metil-N-metansulfonilamino) pirimidina de la fórmula (3). [R es un grupo hidrocarbilo], se prepara por medio de los pasos de: (I) hacer reaccionar un éster de isobutirilacetato con 4-florobenzaldehído y urea ante la presencia de un compuesto protónico y una sal de metal; (II) oxidar el producto de la reacción del paso (I); (III) hacer reaccionar el producto de la reacción del paso (II) con un haluro sulfonilo orgánico o anhídrido de sulfonilo orgánico; y (IV) hacer reaccionar el producto de la reacción del paso (III) con N-metil-N-metanosulfonamida.
ARP020102617A 2001-07-13 2002-07-12 Preparacion de los compuestos de aminopirimidina AR034772A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2001213417 2001-07-13
JP2001213418 2001-07-13
JP2001310900 2001-10-09
JP2001360339 2001-11-27
JP2002007015 2002-01-16
JP2002042076 2002-02-19

Publications (1)

Publication Number Publication Date
AR034772A1 true AR034772A1 (es) 2004-03-17

Family

ID=27554967

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020102617A AR034772A1 (es) 2001-07-13 2002-07-12 Preparacion de los compuestos de aminopirimidina
ARP110103194A AR082864A2 (es) 2001-07-13 2011-09-01 Preparacion de compuestos de aminopirimidina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110103194A AR082864A2 (es) 2001-07-13 2011-09-01 Preparacion de compuestos de aminopirimidina

Country Status (28)

Country Link
US (4) US7304156B2 (es)
EP (1) EP1417180B1 (es)
JP (2) JP4359141B2 (es)
KR (1) KR100888408B1 (es)
CN (2) CN100349877C (es)
AR (2) AR034772A1 (es)
AT (1) ATE349431T1 (es)
AU (1) AU2002318041B2 (es)
BR (1) BR0211072A (es)
CA (1) CA2453505C (es)
CO (1) CO5560574A2 (es)
CY (1) CY1107551T1 (es)
DE (1) DE60217126T2 (es)
DK (1) DK1417180T3 (es)
EG (1) EG24848A (es)
ES (1) ES2278032T3 (es)
HK (1) HK1064384A1 (es)
HU (1) HUP0401248A3 (es)
IL (2) IL159741A0 (es)
IS (1) IS2399B (es)
MX (1) MXPA04000322A (es)
MY (1) MY133579A (es)
NO (1) NO326173B1 (es)
NZ (1) NZ531033A (es)
PL (1) PL366831A1 (es)
PT (1) PT1417180E (es)
SI (1) SI1417180T1 (es)
WO (1) WO2003006439A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
BR0211072A (pt) 2001-07-13 2004-12-14 Astrazeneca Uk Ltd Processo para preparar um composto, composto, e, método para a preparação de um composto
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DE60330050D1 (de) * 2002-12-16 2009-12-24 Astrazeneca Uk Ltd Verfahren zur herstellung von pyrimidinverbindungen
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
SI2024341T1 (sl) * 2006-05-03 2016-04-29 Msn Laboratories Private Limited Novi postopek za statine in njihove farmacevtsko sprejemljive soli
ES2567171T3 (es) 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
CN101323597B (zh) * 2007-06-11 2012-09-05 安徽省庆云医药化工有限公司 4-(4-氟苯基)-6-异丙基-2-(n-甲基-n-甲磺酰氨基)嘧啶-5-甲醛的制备方法
CN101376647B (zh) * 2007-08-31 2010-12-08 中山奕安泰医药科技有限公司 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法
US20110201634A1 (en) * 2008-06-13 2011-08-18 Delhi University Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
EP2423195A1 (en) 2010-07-26 2012-02-29 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
CN101955463B (zh) * 2010-08-04 2012-01-04 重庆博腾制药科技股份有限公司 瑞舒伐他汀钙中间体的制备方法
CN102584717B (zh) * 2011-01-17 2014-12-10 浙江九洲药业股份有限公司 用于制备罗苏伐他汀的中间体及相关制备方法和用途
WO2013185309A1 (zh) * 2012-06-13 2013-12-19 上海迪赛诺药业有限公司 瑞舒伐他汀钙及其中间体的制备方法
CN103483269B (zh) * 2012-06-13 2016-04-27 上海迪赛诺药业有限公司 瑞舒伐他汀钙及其中间体的制备方法
CN103864697A (zh) * 2012-12-11 2014-06-18 润泽制药(苏州)有限公司 瑞舒伐中间体主链醇的制备方法
CN104059024B (zh) * 2014-06-16 2016-04-06 浙江大学 瑞舒伐他汀中间体的制备方法及中间体化合物
MX368055B (es) * 2015-01-23 2019-09-18 Dsm Sinochem Pharm Nl Bv Procedimiento mejorado para preparar un precursor de estatina.
CN104817505A (zh) * 2015-04-23 2015-08-05 南京博优康远生物医药科技有限公司 一种制备n-[4-(4-氟苯基)-5-羟甲基-6-异丙基-嘧啶-2-基]-n-甲基甲磺酰胺的方法
CN109912522B (zh) * 2017-12-12 2021-04-13 北京颖泰嘉和生物科技股份有限公司 制备三唑啉硫酮化合物的方法
CN109081815A (zh) * 2018-11-12 2018-12-25 甘肃农业大学 一种新型亲电试剂甲磺酸嘧啶酯的制备方法
CN111138369A (zh) * 2019-12-17 2020-05-12 上海雅本化学有限公司 瑞舒法他汀中间体的制备方法
AU2021242143A1 (en) * 2020-03-27 2022-10-20 Dong-A St Co., Ltd. Aminopyrimidine derivatives and their use as Aryl hydrocarbon receptor modulators
CN112174898B (zh) * 2020-11-06 2021-05-04 浙江宏元药业股份有限公司 一种连续氧化二氢嘧啶酮制备羟基嘧啶的新方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) * 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
US4625039A (en) * 1983-12-21 1986-11-25 Sandoz Pharm. Corp. 4-trisubstituted silyl protected hydroxy-6-oxo-tetrahydropyran-2-yl-aldehyde intermediates
US4650890A (en) * 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4677211A (en) * 1984-06-29 1987-06-30 Sandoz Pharmaceuticals Corp. Preparation of lactones
US4808621A (en) 1986-07-07 1989-02-28 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4957971A (en) * 1986-07-07 1990-09-18 Warner-Lambert Company Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US5102893A (en) * 1986-07-07 1992-04-07 Warner-Lambert Company Trans-6-(2-(n-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl- or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
DE3739882A1 (de) * 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine
DE3741508A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Wasserloesliche disazoverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
GB2244706B (en) 1988-02-18 1992-07-15 Bristol Myers Co Preparation of antihypercholesterolemic tetrazole intermediates
EP0367895A1 (en) 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
IE914005A1 (en) * 1990-12-14 1992-06-17 Zeneca Ltd Novel intermediates
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) * 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
EP0577040B1 (de) * 1992-07-02 1997-09-24 Hoechst Aktiengesellschaft Verfahren zur Herstellung von (3R,5S)6-Hydroxy-3,5-0-isopropyliden-3,5-dihydroxy-hexansäure-tert.-butylester
JP3197971B2 (ja) 1993-03-01 2001-08-13 塩野義製薬株式会社 ５−カルボアルコキシピリミジン誘導体の合成方法
CZ151297A3 (cs) 1994-11-16 1998-07-15 Synaptic Pharmaceutical Corporation Dihydropyrimidinové sloučeniny a farmaceutické prostředky na jejich bázi
DE19517186A1 (de) 1995-05-11 1996-11-14 Bayer Ag Verfahren zur Herstellung substituierter 2-Fluor-pyrimidine
US6278001B1 (en) 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
WO1997021687A1 (en) 1995-12-14 1997-06-19 Merck & Co., Inc. Process for making dihydropyrimidinones
CA2297889A1 (en) 1997-08-05 1999-02-18 Norihiro Ikemoto Alpha 1a adrenergic receptor antagonist
CZ299566B6 (cs) * 1998-12-10 2008-09-03 Kaneka Corporation Zpusob výroby simvastatinu
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
WO2000078730A1 (fr) 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Nouveaux derives dihydropyrimidiniques
JP2003504070A (ja) 1999-07-09 2003-02-04 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツング ケトカルボン酸及びそのエステルの還元のための方法
CZ304307B6 (cs) * 1999-07-13 2014-02-26 Lonza Ag Způsob výroby 2-amino-4-(4-fluorfenyl)-6-alkyl-pyrimidin-5-karboxylátu
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
US8374574B1 (en) 2000-07-06 2013-02-12 Motorola Mobility Llc Method and apparatus for storing a message for playback during a user-initiated emergency telephone call from a wireless device
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
WO2002098854A2 (en) * 2001-06-06 2002-12-12 Bristol-Myers Squibb Company Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
HUP0401145A3 (en) 2001-07-06 2008-08-28 Ciba Sc Holding Ag Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof
BR0211072A (pt) * 2001-07-13 2004-12-14 Astrazeneca Uk Ltd Processo para preparar um composto, composto, e, método para a preparação de um composto
EP1423365A1 (en) 2001-08-22 2004-06-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of indole derivatives
EP1323717A1 (en) * 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
BR0311195A (pt) 2002-05-21 2005-02-22 Ranbaxy Lab Ltd Processo de preparação de rosuvastatina
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
ATE501126T1 (de) 2002-12-10 2011-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von rosuvastatin
DE60330050D1 (de) * 2002-12-16 2009-12-24 Astrazeneca Uk Ltd Verfahren zur herstellung von pyrimidinverbindungen
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) * 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
CA2550742A1 (en) 2003-12-24 2005-07-14 Teva Pharmaceutical Industries Ltd. Process for preparation of statins with high syn to anti ratio
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
JP5178841B2 (ja) 2008-10-29 2013-04-10 三菱電機株式会社 空気調和装置

Also Published As

Publication number Publication date
HK1064384A1 (en) 2005-01-28
NO20040122L (no) 2004-01-12
DE60217126D1 (de) 2007-02-08
JP2004536849A (ja) 2004-12-09
EP1417180A1 (en) 2004-05-12
CA2453505A1 (en) 2003-01-23
NZ531033A (en) 2005-07-29
IS2399B (is) 2008-09-15
CO5560574A2 (es) 2005-09-30
WO2003006439A1 (en) 2003-01-23
DK1417180T3 (da) 2007-04-10
SI1417180T1 (sl) 2007-04-30
PL366831A1 (en) 2005-02-07
JP4359141B2 (ja) 2009-11-04
EP1417180B1 (en) 2006-12-27
HUP0401248A3 (en) 2004-11-29
IL159741A (en) 2009-06-15
NO326173B1 (no) 2008-10-13
CA2453505C (en) 2011-04-19
CN1763016A (zh) 2006-04-26
US8222412B2 (en) 2012-07-17
US20110160455A1 (en) 2011-06-30
CY1107551T1 (el) 2013-03-13
MXPA04000322A (es) 2005-09-08
DE60217126T2 (de) 2007-10-04
KR100888408B1 (ko) 2009-03-13
JP5016583B2 (ja) 2012-09-05
KR20040030051A (ko) 2004-04-08
US20120277432A1 (en) 2012-11-01
HUP0401248A2 (hu) 2004-10-28
ATE349431T1 (de) 2007-01-15
AU2002318041B2 (en) 2008-01-03
BR0211072A (pt) 2004-12-14
IS7103A (is) 2004-01-12
JP2009167167A (ja) 2009-07-30
IL159741A0 (en) 2004-06-20
US8614320B2 (en) 2013-12-24
ES2278032T3 (es) 2007-08-01
EG24848A (en) 2010-10-27
PT1417180E (pt) 2007-03-30
MY133579A (en) 2007-11-30
AR082864A2 (es) 2013-01-16
US7816528B2 (en) 2010-10-19
US7304156B2 (en) 2007-12-04
US20040176401A1 (en) 2004-09-09
EP1417180A4 (en) 2004-10-27
CN1301977C (zh) 2007-02-28
CN100349877C (zh) 2007-11-21
US20080058520A1 (en) 2008-03-06
CN1527821A (zh) 2004-09-08

Similar Documents

Publication Publication Date Title
AR034772A1 (es) Preparacion de los compuestos de aminopirimidina
NO20025719D0 (no) Nye triazolpyrimidinforbindelser
EA200201071A1 (ru) Циклопентилзамещенные производные глутарамида в качестве ингибиторов нейтральной эндопептидазы
ES2195510T3 (es) Derivados de imidazopiridina y procedimiento para prepararlos.
IT1263089B (it) Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono.
EP1279665A3 (en) A process for the preparation of perindopril, its analogous compounds and salts thereof using 2,5-dioxo-oxazolidine intermediate compounds
EP1069112A4 (en) N- (PHENYLSULFONYL) PICOLINAMIDE DERIVATIVES, METHOD FOR THEIR PREPARATION AND HERBICIDES
ES2159488A1 (es) Procedimiento para la preparacion de derivados de pirimidona con actividad antifugica.
PT1165485E (pt) Processo para a preparacao de produtos intermediarios pesticidas
CO4950549A1 (es) Procedimiento
AR029452A1 (es) Compuestos de 4-amino-3-alcoxiiminapirrolidina, utilizables en la preparacion de derivados de acidos quinolincarboxilicos y de sales e hidratos farmaceuticamente aceptables de los mismos y procedimiento de preparacion de dicho compuesto, respectivamente de dichos derivados
BR0004787A (pt) Processo para a preparação de compostos pirazolo[4,3-d] pirimidin-7-onas-3-piridilsulfonila bem como intermediários dos mesmos
DK0897924T3 (da) Fremgangsmåde til fremstilling af tetrahydroindoliziner
AU1890299A (en) Potassium channel activators
DE60203890D1 (de) Apfelsäureadditionssalze von terbinafin
SE0101323D0 (sv) New process
IS6636A (is) Hringlaga ketonar og notkun þeirra í smíði amínósýra
ATE356118T1 (de) Moexipril-magnesium enthaltende arzneimittel
DK0994851T3 (da) Fremgangsmåde til fremstilling af 2-alkylthio-substiuerede benzoesyrederivater
DK1326607T3 (da) Farmaceutisk sammensætning omfattende oxapenem-3-carboxylsyrer
BR0009795A (pt) Processo para a ppeparação de um composto da fórmula (i), e, composto
DK1424329T3 (da) Fremgangsmåde til fremstillingen af 4-(imidazol-1-yl)benzensulfonamid
PT1421064E (pt) Processo para a preparacao de derivados de 3-espiro'ciclohexan-1,3'-'3h}indolin-2'-ona}
DK1075461T3 (da) Perfluorerede estere af alkanoyl-L-carnitin til fremstillingen af kationiske lipider til den intracellulære levering af farmakologisk aktive forbindelser
EA200200636A1 (ru) Новые соединения 3-имино-1,2-дитиола, способ их получения и фармацевтические композиции, их содержащие

Legal Events

Date Code Title Description
FC Refusal